Champions Oncology (NASDAQ: CSBR) details Q1 FY2025 results in 8-K

Rhea-AI Filing Summary

Champions Oncology, Inc. filed a current report to note that it issued a press release covering its unaudited financial results for the first quarter ended July 31, 2025. The press release is provided as Exhibit 99.1 to the report so investors can review the detailed quarterly information.

The company states that the information under this earnings item is being furnished, not filed, under securities law, which affects how it is treated for certain legal purposes and future SEC filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/15/2025 - 04:47 PM Learn about SEC filing dates

FAQ

What did Champions Oncology (CSBR) disclose in this 8-K?

Champions Oncology disclosed that it issued a press release announcing its unaudited financial results for the first quarter ended July 31, 2025, and attached that release as Exhibit 99.1.

Which period do the disclosed Champions Oncology (CSBR) results cover?

The press release referenced in the report covers Champions Oncology’s unaudited financial results for its first quarter ended July 31, 2025.

How is the earnings information in this Champions Oncology (CSBR) 8-K treated under securities laws?

The company states that the information provided under the earnings item is furnished, not filed, for purposes of the Securities Exchange Act of 1934, which affects its treatment under certain liability and incorporation-by-reference rules.

Where can investors find the detailed Q1 FY2025 results for Champions Oncology (CSBR)?

Investors can find the detailed Q1 FY2025 results in the press release that Champions Oncology attached to the report as Exhibit 99.1.

Who signed the Champions Oncology (CSBR) 8-K related to Q1 FY2025 results?

The report was signed on behalf of Champions Oncology, Inc. by Robert Brainin, who is identified as the Chief Executive Officer.

Does this Champions Oncology (CSBR) 8-K include the full financial statements?

The report itself announces the issuance of a press release with unaudited first-quarter financial results and indicates that the press release is attached as Exhibit 99.1, where the detailed figures are provided.

0000771856false00007718562025-09-152025-09-15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 15, 2025

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-11504

52-1401755

(State or Other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (201) 808-8400

N/A

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

CSBR

The Nasdaq Stock Market LLC

    

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

INFORMATION TO BE INCLUDED IN THE REPORT

Item 2.02. Results of Operations and Financial Condition.

On September 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

The following exhibit is filed herewith:

Exhibit No.

99.1 Press Release dated September 15, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						CHAMPIONS ONCOLOGY, INC.
						(Registrant)
Date: September 15, 2025			By:			/s/ Robert Brainin
						Robert Brainin
						Chief Executive Officer